J&J acquisition of Ambrx bolsters cancer ADC portfolio amidst big pharma’s growing investment trend: GlobalData
Express Pharma
JANUARY 10, 2024
ARX788 contains a trastuzumab-based antibody conjugated to two AS269 proprietary tubulin-inhibiting cytotoxic payloads. ARX788 contains a trastuzumab-based antibody conjugated to two AS269 proprietary tubulin-inhibiting cytotoxic payloads. GlobalData projects the drug to earn $534 million by 2029.
Let's personalize your content